The Medicity has launched a public awareness campaign to shift the focus from seasonal concern over air pollution to continuous monitoring and prevention of chronic respiratory diseases (CRDs).
MedGenome invests in Medcare to strengthen India’s integrated diagnostics ecosystem, combining advanced imaging, pathology, and genomics for better early disease detection.
Zydus Lifesciences has received final USFDA approval for its Ivermectin Tablets 3 mg and Dapsone Tablets 25 mg and 100 mg, further expanding its global pharmaceutical footprint.
Eli Lilly and Company reported that its investigational oral GLP-1 receptor agonist, orforglipron, achieved superior blood sugar control and weight loss compared with oral semaglutide in a head-to-head phase 3 trial in adults with type 2 diabet...
Boehringer Ingelheim has received FDA approval for its drug Ofev as a first-line treatment for non-small cell lung cancer. The approval offers a new option for patients with metastatic NSCLC, combining Ofev with chemotherapy for better outcomes.
Lupin Limited has announced FDA approval for its Brivaracetam Oral Solution 10 mg/mL, a bioequivalent of UCB’s Briviact, designed to treat partial-onset seizures in patients 1 month and older. The launch is now underway in the U.S.
Gleneagles Hospital, Mumbai, partners with Medtronic India to launch a Renal Denervation Therapy Centre, offering advanced treatment for resistant hypertension and improving outcomes.
Bayer's Nubeqa receives expanded approval in India for metastatic hormone-sensitive prostate cancer, offering a non-chemotherapy treatment with ADT for advanced cases.
Lilly and Company has announced that its Retevmo (selpercatinib) has met its primary endpoint in the LIBRETTO-432 Phase 3 trial, showing a significant improvement in event-free survival for early-stage RET fusion-positive NSCLC patients.
Novartis announces sale of 70.68% stake in Novartis India for Rs 1,446 crore, with an offer to buy an additional 26% from public shareholders, marking a major strategic shift.